Karine joined Erytech Pharma in September 2017, leading early-stage program strategy first as Director, Business Development and now as Director, Innovation and Valorization (R&D and BD&L activities). In her current role, she is leading Erytech’s early-stage development efforts to utilize the Company’s proprietary platforms to develop red blood cell-based therapeutics for rare disease and oncology. She manages all facets of program derisking and additionally creates development value through scouting, evaluating potential licensing opportunities and partnerships, and leading IP and grant financing strategy.  Prior to joining Erytech Pharma, Karine was a Researcher in charge of R&D programs in the non-profit company Généthon, dedicated to developing gene therapies for rare diseases, where she developed deep experience in innovative product development in gene therapy space.  She then moved to the Scientific Direction of AFM-Téléthon to support detection, valorization and follow-up of projects to be funded in the field of rare diseases.